Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.

None © Credit: University of Oxford, John Cairns

Severe necrotizing soft tissue infections (SENSEI) study: Protocol for a multi-centered audit.

Journal article

Yoshimura R. et al, (2026), JPRAS Open, 48, 331 - 336

Securing the future of immunisation: ESCMID’s vision

Journal article

Ramasamy MN. et al, (2026), CMI Communications, 3, 105167 - 105167

Enablers and barriers to participation in vaccine trials: a narrative synthesis.

Journal article

Daniel N. et al, (2026), Vaccine, 73

A risk to child health: confusion and concern over changes to US vaccine policy.

Journal article

Pollard AJ. and Plotkin S., (2026), Lancet, 407, 553 - 556

Load More